Published in Mol Pharmacol on November 30, 2007
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J Am Soc Nephrol (2014) 1.13
Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila) (2008) 1.10
Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res (2010) 1.03
Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration. J Biol Chem (2010) 1.01
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. PLoS One (2011) 0.96
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol (2011) 0.95
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer (2012) 0.95
Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia (2010) 0.92
Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia (2008) 0.90
Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer. PPAR Res (2008) 0.89
The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer. PPAR Res (2008) 0.84
Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression. Mol Cancer (2015) 0.83
To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. PPAR Res (2008) 0.83
ω3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients. PLoS One (2013) 0.83
Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways. Mol Cancer Ther (2008) 0.83
Critical role of PPARγ in myeloid-derived suppressor cell-stimulated cancer cell proliferation and metastasis. Oncotarget (2016) 0.82
HuR and TTP: two RNA binding proteins that deliver message from the 3' end. Gastroenterology (2009) 0.81
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. Oncoimmunology (2012) 0.80
Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. Biomed Res Int (2014) 0.79
Transcriptional and Non-Transcriptional Functions of PPARβ/δ in Non-Small Cell Lung Cancer. PLoS One (2012) 0.78
PPARγ in head and neck cancer prevention. Oral Oncol (2014) 0.77
Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. PLoS One (2015) 0.77
Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer. World J Biol Chem (2010) 0.77
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword. PPAR Res (2012) 0.77
The use of Cox-2 and PPARγ signaling in anti-cancer therapies. Exp Ther Med (2010) 0.76
α-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-γ activation and COX-2 inhibition. Oncol Lett (2013) 0.75
Inhibition of hypoxia-induced cyclooxygenase-2 by Korean Red Ginseng is dependent on peroxisome proliferator-activated receptor gamma. J Ginseng Res (2016) 0.75
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 3.09
Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol (2008) 2.71
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol (2005) 2.39
Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res (2003) 2.00
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood (2004) 1.95
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One (2010) 1.69
Embryonic growth-associated protein is one subunit of a novel N-terminal acetyltransferase complex essential for embryonic vascular development. Circ Res (2006) 1.54
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A (2003) 1.53
Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem (2005) 1.53
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg (2012) 1.49
Depletion of serum response factor by RNA interference mimics the mitogenic effects of platelet derived growth factor-BB in vascular smooth muscle cells. Circ Res (2005) 1.48
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res (2002) 1.47
C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol (2007) 1.45
Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase. Proc Natl Acad Sci U S A (2002) 1.43
Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem (2006) 1.40
Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene (2005) 1.40
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res (2012) 1.37
Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog (2004) 1.32
Reductive iron uptake by Candida albicans: role of copper, iron and the TUP1 regulator. Microbiology (2002) 1.31
Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res (2002) 1.31
Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res (2011) 1.27
Platelet-derived growth factor-BB-mediated activation of Akt suppresses smooth muscle-specific gene expression through inhibition of mitogen-activated protein kinase and redistribution of serum response factor. J Biol Chem (2003) 1.26
Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest (2002) 1.24
Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol (2002) 1.23
Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res (2004) 1.22
Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J Immunol (2004) 1.21
Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Mol Cell Biol (2005) 1.21
Downregulation of Dlx5 and Dlx6 expression by Hand2 is essential for initiation of tongue morphogenesis. Development (2011) 1.20
gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene (2002) 1.19
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis (2004) 1.16
Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res (2002) 1.16
Wnt signaling pathway and lung disease. Transl Res (2008) 1.16
Beta-catenin in the fibroproliferative response to acute lung injury. Am J Respir Cell Mol Biol (2005) 1.15
Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. Cardiovasc Res (2010) 1.14
Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS One (2010) 1.12
Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol (2013) 1.10
The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat (2009) 1.10
Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell (2008) 1.10
Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila) (2008) 1.10
Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol (2003) 1.05
Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res (2010) 1.03
Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. PLoS One (2012) 1.03
Inhibited neurogenesis in JNK1-deficient embryonic stem cells. Mol Cell Biol (2005) 1.01
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res (2013) 1.01
FAK induces expression of Prx1 to promote tenascin-C-dependent fibroblast migration. J Cell Biol (2003) 1.00
Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. Clin Cancer Res (2012) 0.97
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. PLoS One (2011) 0.96
Modulation of bone marrow-derived neutrophil signaling by H2O2: disparate effects on kinases, NF-kappaB, and cytokine expression. Am J Physiol Cell Physiol (2003) 0.96
Induction of SM-alpha-actin expression by mechanical strain in adult vascular smooth muscle cells is mediated through activation of JNK and p38 MAP kinase. Biochem Biophys Res Commun (2003) 0.96
Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res (2009) 0.95
Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res (2011) 0.94
Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia (2010) 0.94
Multiple signaling conduits regulate global differentiation-specific gene expression in PC12 cells. J Cell Physiol (2004) 0.94
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med (2013) 0.92
Differential gene regulation by specific gain-of-function JNK1 proteins expressed in Swiss 3T3 fibroblasts. J Biol Chem (2002) 0.92
Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia (2010) 0.92
Extracellular ATP-induced proliferation of adventitial fibroblasts requires phosphoinositide 3-kinase, Akt, mammalian target of rapamycin, and p70 S6 kinase signaling pathways. J Biol Chem (2004) 0.91
Collaboration of JNKs and ERKs in nerve growth factor regulation of the neurofilament light chain promoter in PC12 cells. J Biol Chem (2001) 0.91
Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. Mol Pharmacol (2002) 0.90
Patterns of gene expression differentially regulated by platelet-derived growth factor and hypertrophic stimuli in vascular smooth muscle cells: markers for phenotypic modulation and response to injury. J Biol Chem (2005) 0.90
Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer. PPAR Res (2008) 0.89
Adipose lineage specification of bone marrow-derived myeloid cells. Adipocyte (2012) 0.88
Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice. Carcinogenesis (2004) 0.88
Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell (2003) 0.88
Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res (2006) 0.88
Attenuation of the pulmonary inflammatory response following butylated hydroxytoluene treatment of cytosolic phospholipase A2 null mice. Am J Physiol Lung Cell Mol Physiol (2006) 0.87
Ectodermal-derived Endothelin1 is required for patterning the distal and intermediate domains of the mouse mandibular arch. Dev Biol (2012) 0.86
Serum response factor regulates expression of phosphatase and tensin homolog through a microRNA network in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2011) 0.83